Publication | Closed Access

E2F suppression and Sp1 overexpression are sufficient to induce the differentiation-specific marker, transglutaminase type 1, in a squamous cell carcinoma cell line

Tumor BiologyDifferentiation-specific MarkerOncogenic AgentMedicinePathologyTransglutaminase Type 1Tumor SuppressorCancer GeneticsOncologyCell BiologyCancer ResearchE2f Suppression